<!doctype html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/css/bootstrap.min.css" integrity="sha384-JcKb8q3iqJ61gNV9KGb8thSsNjpSL0n8PARn9HuZOnIxN0hoP+VmmDGMN5t9UJ0Z" crossorigin="anonymous">
    <link rel="stylesheet" href="./style.css" />
    <script src="https://kit.fontawesome.com/5901743741.js"></script>
    <title>NeuroPn</title>
  </head>
  <body>
    <nav class="navbar navbar-expand-lg">
        <button class="brand-button">
            <a class="navbar-brand" href="index.html">NeuroPn</a>
        </button>
        <button class="navbar-toggler" data-toggle="collapse" data-target="#navbar-menu">
            <i class="fas fa-bars menu"></i>
        </button>
        <div id="navbar-menu" class="collapse navbar-collapse">
            <ul class="navbar-nav ml-auto">
                <li class="nav-item">
                <a class="nav-link" href="index.html">Home</a>
                </li>
                <li class="nav-item">
                    <a class="nav-link" href="team.html">Our Team</a>
                </li>
                <li class="nav-item">
                    <a class="nav-link" href="science.html">Our Science</a>
                </li>
                <li class="nav-item">
                    <a class="nav-link" href="contact.html">Contact Us</a>
                </li>
            </ul>    
       </div>
    </nav>
    
    <div id="my-carousel" class="carousel slide carousel-fade" data-ride="carousel">
        <ol class="carousel-indicators">
            <li data-target="#my-carousel" data-slide-to="0" class="active"></li>
            <li data-target="#my-carousel" data-slide-to="1"></li>
            <li data-target="#my-carousel"  data-slide-to="2"></li>
            <li data-target="#my-carousel"  data-slide-to="3"></li>
        </ol>
        <div class="carousel-inner"> 
            <div id="item-1" class="carousel-item active" data-interval="5000">
                <div class="overlay-image"></div>
                <div class="container">
                    <h1 class="header">NeuroPn <span class="new-color">Therapeutics</span></h1>
                    <h5 class="caption width-control">Innovative Therapies for Neuro Degenerative Diseases</h5>
                </div>
            </div>
            <div id="item-2" class="carousel-item" data-interval="5000">
                <div class="overlay-image"></div>
                <div class="container"> 
                    <h1 class="header">NeuroPn <span class="new-color">Therapeutics</span></h1>
                    <h5 class="caption width-control">Non-narcotic safer treatments for pain</h5>
                </div>
            </div>
            <div id="item-3" class="carousel-item" data-interval="5000">
                <div class="overlay-image"></div>
                <div class="container"> 
                    <h1 class="header">NeuroPn <span class="new-color">Therapeutics</span></h1>
                    <h5 class="caption width-control">Disease Modification</h5>
                </div>
            </div>
            <div id="item-4" class="carousel-item" data-interval="5000">
                <div class="overlay-image"></div>
                <div class="container"> 
                    <h1 class="header">NeuroPn <span class="new-color">Therapeutics</span></h1>
                    <h5 class="caption width-control">Neuronal Protection</h5>
                </div>
            </div>
        </div> 
        <a class="carousel-control-prev" href="#my-carousel" role="button" data-slide="prev">
            <span class="carousel-control-prev-icon" aria-hidden="true"></span>
            <span class="sr-only">Previous</span>
          </a>
          <a class="carousel-control-next" href="#my-carousel" role="button" data-slide="next">
            <span class="carousel-control-next-icon" aria-hidden="true"></span>
            <span class="sr-only">Next</span>
          </a>
    </div>

    <div class="home-content">
        <h2 class="about-heading">What we do</h2>
        <p> NeuroPn Therapeutics is working on novel and improved therapies for the treatment of neurodegenerative diseases 
            with focus on painful peripheral neuropathy and Parkinson's disease. 
        </p>
        <div class="science-container">
            <h4 class="science-title">Painful Peripheral Neurotheraphy</h4>
            <p> NeuroPn is developing a novel, potential disease modifying approach to treat peripheral neuropathic pain. </p>
            <button class="btn learn-btn" type="button" data-toggle="collapse" data-target="#learn-more-one" aria-expanded="false" aria-controls="collapseExample">
                Learn More
            </button>
            <div class="collapse" id="learn-more-one">
                <div class="card card-body">
                    <p> Painful peripheral neuropathy [PPN] is caused by an injury or inflammation of the nervous system. PPN is 
                        associated with diseases such as diabetes or use of drugs such as chemotherapeutic agents or antiviral 
                        drugs.  Peripheral neuropathies may involve injured sensory, motor, or autonomic nervous system nerves. 
                        In the central nervous system, injury, stroke, or disease in the brain or spinal cord can also generate 
                        a state of chronic neuropathic pain. Pain associated with acute neuronal damage can also transition to 
                        chronic pain. 
                    </p>
                    <div class="science-image">
                        <img src="ppn.jpeg">
                    </div>
                    <p> Peripheral neuropathic pain affects over 16 million Americans and is causally linked to a number 
                        of diseases including diabetes, cancer, shingles, infections such as HIV, chronic back pain, stroke, 
                        and multiple sclerosis . The most commonly prescribed drug classes for neuropathic pain such as 
                        antidepressants, serotonin-norepinephrine reuptake inhibitors, anticonvulsants and opioids, have 
                        limited efficacy and dose-limiting adverse effects. No single agent provides optimal balance of safety, 
                        tolerability, and efficacy. As a result, treatment of peripheral neuropathy continues to be characterized 
                        by a high rate of polypharmacy and switching from one agent to another.
                    </p>
                    <p> All currently approved treatments for PPN modulate neuronal targets and provide only symptomatic relief. </p>
                    <p> NeuroPn Approach- NeuroPn is pursuing an enzyme target that has the potential to be a disease modifying 
                        approach to treat peripheral neuropathic pain.
                    </p>
                    <ul>
                        <li> NeuroPn has identified a series of novel, orally active, potent enzyme inhibitors that are effective 
                            in animal models of acute and chronic peripheral neuropathic pain.
                        </li>
                        <li> In animal models of nerve injury, NeuroPn compounds prevent neuronal damage and promote nerve 
                            healing. 
                        </li>
                        <li> Unlike opioids and other centrally acting agents, NeuroPn treatment is not associated with narcotic 
                            and other CNS adverse effects.
                        </li>
                        <li> In chronic toxicology studies NeuroPn compounds exhibited clean safety profile with high therapeutic 
                            window.
                        </li>
                    </ul>
                    <p> NeuroPn compounds present a novel approach to treat painful peripheral neuropathy with highly 
                        discriminatory profile (improved efficacy, clean CNS safety profile and neuronal protection) vs 
                        marketed drugs. 
                    </p>
                </div>
            </div>
        </div>
        <div class="science-container">
            <h4 class="science-title">Parkinson's Disease</h4>
            <p> NeuroPn's enzyme inhibition approach shows marked improvement in locomotor activity and significant inhibition 
                of neuronal degeneration; differentiating from current satandard of care (L-DOPA). 
            </p>
            <button class="btn learn-btn" type="button" data-toggle="collapse" data-target="#learn-more-two" aria-expanded="false" aria-controls="collapseExample">
                Learn More
            </button>
            <div class="collapse" id="learn-more-two">
                <div class="card card-body">
                    <p> Parkinsons’s disease (PD) is a chronic and progressive degenerative movement disorder that affects over 
                        1.5 million Americans. Currently marketed dopamine replacement therapy can alleviate motor symptoms in 
                        PD, but there are no therapies that target the underlying neurodegenerative processes. Despite intense 
                        research, molecular mechanisms causing neuronal loss are not fully understood which has hampered the 
                        development of new drugs and disease modifying therapies.
                    </p>
                    <p> Neuroinflammation and mitochondrial dysfunction with associated oxidative/endoplasmic reticulum (ER) 
                        stress all work synergistically to accelerate Parkinson’s disease (PD) progression.
                    </p>
                    <div class="science-image">
                        <img src="parkinson.jpeg">
                    </div>
                    <p class="card-subheading">NeuroPn’s target enzyme has been extensively validated in PD studies </p>
                    <ul>
                        <li> The target is widely expressed in brain and it's levels are elevated in PD models and patients. </li>
                        <li> In PD and DLB patints enzyme levels correlate with synuclein deposition. </li>
                        <li> In neuronal cells, target inhibition prevents endoplasmic reticulum (ER) and oxidative stress and 
                            neuroinflammation a key contributor to loss of dopaminergic neurons.
                        </li>
                        <li> Target modulation enhances axonal growth in primary sensory and cortical neuronal cell cultures. </li>
                    </ul>
                    <p class="card-subheading"> NeuroPn enzyme inhibitors in multiple models of PD </p>
                    <ul>
                        <li> Improved locomotor activity without hyperactivity typically seen with L-DOPA. </li>
                        <li> Prevented neuronal cell damage differentiating from L-DOPA. </li>
                        <li> In therapeutic models of PD with established disease NeuroPn compounds revered PD symptoms. </li>
                        <li> In chronic toxicology studies, NeuroPn compound exhibited a clean safety profile . </li>
                    </ul>
                    <p class="card-endnote">The preclinical studies conducted establish NeuroPn approach as a disease modifying approach with 
                        clear differentiation from L-DOPA.
                    </p>
                </div>
            </div>
        </div>
    </div>

    <footer>
        <h5 class="footer-title">NeuroPn</h5>
        <div class="footer-content">
            <p class="footer-address">
                <span>4989 Peachtree Parkway</span>
                <span>Suite 200</span>
                <span>Peachtree Parkway</span>
                <span>GA 30092 USA</span>
            </p>
            <p class="footer-contact">
                <span>404-939-5786</span>
                <span>business@neuropn.com</span>
            </p>
        </div>
    </footer>

    <!-- Optional JavaScript -->
    <!-- jQuery first, then Popper.js, then Bootstrap JS -->
    <script src="https://code.jquery.com/jquery-3.5.1.slim.min.js" integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/npm/popper.js@1.16.1/dist/umd/popper.min.js" integrity="sha384-9/reFTGAW83EW2RDu2S0VKaIzap3H66lZH81PoYlFhbGU+6BZp6G7niu735Sk7lN" crossorigin="anonymous"></script>
    <script src="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js" integrity="sha384-B4gt1jrGC7Jh4AgTPSdUtOBvfO8shuf57BaghqFfPlYxofvL8/KUEfYiJOMMV+rV" crossorigin="anonymous"></script>
  </body>
</html>